Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients

Tacrolimus is a widely used immunosuppressive drug for preventing the rejection of solid organ transplants. The efficacy of tacrolimus shows considerable variability, which might be related to genetic variation among recipients. We conducted a retrospective study of 240 Chinese renal transplant recipients receiving tacrolimus as immunosuppressive drug. The retrospective data of all patients were collected for 40 days after transplantation. Seventeen SNPs of CYP3A5, CYP3A4, COMT, IL-10 and POR were identified by the SNaPshot assay. Tacrolimus blood concentrations were obtained on days 1–3, days 6–8 and days 12–14 after transplantation, as well as during the period of the predefined therapeutic concentration range. Kruskal–Wallis test was used to examine the effect of genetic variation on the tacrolimus concentration/dose ratio (C 0/D) at different time points. Chi-square test was used to compare the proportions of patients who achieved the target C 0 range in the different genotypic groups at weeks 1, 2, 3 and 4 after transplantation. After correction for multiple testing, there was a significant association of C 0/D with CYP3A5*3, CYP3A4*1G and CYP3A4 rs4646437 T>C at different time points after transplantation. The proportion of patients in the IL-10 rs1800871-TT group who achieved the target C 0 range was greater (p = 0.004) compared to the IL-10 rs1800871-CT and IL-10 rs1800871-CC groups at week 3 after transplantation. CYP3A5*3, CYP3A4 *1G, CYP3A4 rs4646437 T>C and IL-10 rs1800871 C>T might be potential polymorphisms affecting the interindividual variability in tacrolimus metabolism among Chinese renal transplant recipients.

[1]  D. Hesselink,et al.  The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. , 2013, British journal of clinical pharmacology.

[2]  J. Barrett,et al.  Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis , 2013, Pharmacogenetics and genomics.

[3]  Jun Yu Li,et al.  Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism – a prospective, randomized, controlled study , 2013, Clinical transplantation.

[4]  K. Verbeke,et al.  In Vivo CYP3A4-Activity, CYP3A5-Genotype and Hematocrit Predict Tacrolimus Dose-Requirements and Clearance in Renal Transplant Recipients: 2026 , 2012 .

[5]  K. Verbeke,et al.  In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients , 2012, Clinical pharmacology and therapeutics.

[6]  V. Haufroid,et al.  The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients , 2012, Pharmacogenetics and genomics.

[7]  V. Haufroid,et al.  A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.

[8]  D. Lambrechts,et al.  The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. , 2011, Pharmacogenomics.

[9]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[10]  L. Kaminsky,et al.  Identification of Cytochrome P450 Oxidoreductase Gene Variants That Are Significantly Associated with the Interindividual Variations in Warfarin Maintenance Dose , 2011, Drug Metabolism and Disposition.

[11]  T. Habuchi,et al.  Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. , 2011, Pharmacogenomics.

[12]  Lei Zheng,et al.  Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay. , 2011, Clinical biochemistry.

[13]  J. Qiu,et al.  A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. , 2011, Basic & clinical pharmacology & toxicology.

[14]  Zhihai Peng,et al.  Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period , 2011, European Journal of Clinical Pharmacology.

[15]  Lei Zheng,et al.  Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study , 2011, European Journal of Clinical Pharmacology.

[16]  A. Israni,et al.  Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium , 2011, Transplantation.

[17]  M. Loriot,et al.  Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing , 2010, Clinical pharmacology and therapeutics.

[18]  V. Haufroid,et al.  Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.

[19]  C. Eap,et al.  CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients , 2008, Therapeutic drug monitoring.

[20]  W. Sadee,et al.  Genotyping panel for assessing response to cancer chemotherapy , 2008, BMC Medical Genomics.

[21]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[22]  P. Nürnberg,et al.  Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. , 2007, Pharmacogenomics.

[23]  V. Haufroid,et al.  CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  Satohiro Masuda,et al.  An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, Pharmacology & therapeutics.

[25]  B. Vinet,et al.  Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients , 2006, Pharmacogenetics and genomics.

[26]  R. Kim,et al.  Genetic variability in CYP3A5 and its possible consequences. , 2004, Pharmacogenomics.

[27]  B. Maes,et al.  Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids , 2004, Clinical pharmacokinetics.

[28]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[29]  P. Syrris,et al.  The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  B. Maes,et al.  Clinical Efficacy and Toxicity Profile of Tacrolimus and Mycophenolic Acid in Relation to Combined Long‐term Pharmacokinetics in de Novo Renal Allograft Recipients , 2004, Clinical pharmacology and therapeutics.

[31]  B. Griffith,et al.  Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism , 2004, Journal of clinical pharmacology.

[32]  E. Schuetz,et al.  Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.